Cosmo Pharmaceuticals’ 2025 annual report said recurring revenue rose 15% year on year, led by continued growth in GI Genius and Winlevi. The company reported EU MDR certification for ColonPRO EU and completed a usability study integrating GI Genius with Apple Vision Pro. Winlevi remained the leading branded topical acne product in the U.S., passed 1.6 million prescriptions since launch, and received EMA approval, with a European rollout planned for 2026. Cosmo also renewed a multi-year manufacturing and supply agreement with Takeda for Mesalazine MMX.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmo Pharmaceuticals NV published the original content used to generate this news brief on March 09, 2026, and is solely responsible for the information contained therein.